Corbus Pharmaceuticals Files 8-K
Ticker: CRBP · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1595097
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: CRBP
TL;DR
CRBP filed an 8-K, but it's light on details. Need to dig deeper.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 15, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or dates beyond the filing date itself. The company is incorporated in Delaware and headquartered in Norwood, Massachusetts.
Why It Matters
This filing indicates a material event has occurred for Corbus Pharmaceuticals, but the lack of detail requires further investigation to understand its implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific information in this particular filing creates uncertainty.
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Norwood, Massachusetts (location) — Principal Executive Offices
- November 15, 2024 (date) — Date of Report
FAQ
What specific event is Corbus Pharmaceuticals Holdings, Inc. reporting in this 8-K filing?
The filing is an 8-K reporting an 'Other Event' but does not provide specific details about the nature of the event.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on November 15, 2024.
What is the principal executive office address for Corbus Pharmaceuticals Holdings, Inc.?
The principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts 02062.
Under which state is Corbus Pharmaceuticals Holdings, Inc. incorporated?
Corbus Pharmaceuticals Holdings, Inc. is incorporated in Delaware.
Does this filing provide any financial figures or dollar amounts?
No, this specific 8-K filing does not contain any specific dollar amounts or financial figures.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-11-15 16:36:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20241115.htm (8-K) — 38KB
- 0000950170-24-127644.txt ( ) — 156KB
- crbp-20241115.xsd (EX-101.SCH) — 31KB
- crbp-20241115_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On November 14, 2024, Anne Altmeyer Ph.D., a member of the board of directors of Corbus Pharmaceuticals Holdings, Inc. (the "Company"), adopted a Rule 10b5-1 plan providing for the sale of up to 2,452 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). Pursuant to this plan, Dr. Altmeyer may sell shares of Common Stock beginning on February 13, 2025, subject to the terms of the agreement, and the plan terminates on December 31, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: November 15, 2024 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer